Delayed
Deutsche Boerse AG
12:31:51 02/02/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.011
EUR
|
-.--%
|
|
-.--%
|
+46.67%
|
Fiscal Period: Juli |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
40.26
|
127.8
|
29.04
|
31.69
|
17.2
|
7.377
|
Enterprise Value (EV)
1 |
42.07
|
127.4
|
30.95
|
35.29
|
21.66
|
11.38
|
P/E ratio
|
-65.9
x
|
-9.74
x
|
-1.98
x
|
-193
x
|
-2.7
x
|
-2.41
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
672
x
|
138
x
|
19.5
x
|
7.58
x
|
6.54
x
|
3.01
x
|
EV / Revenue
|
703
x
|
138
x
|
20.8
x
|
8.45
x
|
8.24
x
|
4.65
x
|
EV / EBITDA
|
-29.2
x
|
-52.9
x
|
-7.26
x
|
47.3
x
|
-3.93
x
|
-3.85
x
|
EV / FCF
|
2,782
x
|
-14.2
x
|
-11.7
x
|
-12.9
x
|
22.9
x
|
-15.3
x
|
FCF Yield
|
0.04%
|
-7.02%
|
-8.54%
|
-7.74%
|
4.36%
|
-6.54%
|
Price to Book
|
20.3
x
|
10.5
x
|
2.16
x
|
2.13
x
|
1.76
x
|
1.06
x
|
Nbr of stocks (in thousands)
|
1,03,233
|
1,18,291
|
1,52,867
|
1,58,426
|
1,63,839
|
1,63,939
|
Reference price
2 |
0.3900
|
1.080
|
0.1900
|
0.2000
|
0.1050
|
0.0450
|
Announcement Date
|
28/11/17
|
28/11/18
|
25/11/19
|
12/11/20
|
29/11/21
|
24/11/22
|
Fiscal Period: Juli |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.0599
|
0.9253
|
1.49
|
4.178
|
2.628
|
2.45
|
EBITDA
1 |
-1.441
|
-2.408
|
-4.263
|
0.7457
|
-5.512
|
-2.953
|
EBIT
1 |
-1.51
|
-2.569
|
-4.85
|
-0.1301
|
-6.335
|
-3.66
|
Operating Margin
|
-2,521.08%
|
-277.65%
|
-325.56%
|
-3.11%
|
-241%
|
-149.4%
|
Earnings before Tax (EBT)
1 |
-0.6049
|
-12.46
|
-12.7
|
-0.1616
|
-6.359
|
-3.066
|
Net income
1 |
-0.6049
|
-12.46
|
-12.7
|
-0.1616
|
-6.359
|
-3.066
|
Net margin
|
-1,010.2%
|
-1,346.42%
|
-852.53%
|
-3.87%
|
-241.94%
|
-125.15%
|
EPS
2 |
-0.005921
|
-0.1109
|
-0.0958
|
-0.001035
|
-0.0389
|
-0.0187
|
Free Cash Flow
1 |
0.0151
|
-8.942
|
-2.644
|
-2.73
|
0.9446
|
-0.7447
|
FCF margin
|
25.26%
|
-966.34%
|
-177.48%
|
-65.33%
|
35.94%
|
-30.4%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/11/17
|
28/11/18
|
25/11/19
|
12/11/20
|
29/11/21
|
24/11/22
|
Fiscal Period: Juli |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
1.81
|
-
|
1.91
|
3.6
|
4.46
|
4
|
Net Cash position
1 |
-
|
0.35
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-1.257
x
|
-
|
-0.4479
x
|
4.833
x
|
-0.8093
x
|
-1.356
x
|
Free Cash Flow
1 |
0.02
|
-8.94
|
-2.64
|
-2.73
|
0.94
|
-0.74
|
ROE (net income / shareholders' equity)
|
-51.9%
|
-176%
|
-98.9%
|
-1.14%
|
-51.6%
|
-36.7%
|
ROA (Net income/ Total Assets)
|
-22%
|
-15%
|
-18.6%
|
-0.41%
|
-20.2%
|
-14.2%
|
Assets
1 |
2.745
|
83.19
|
68.17
|
39.58
|
31.46
|
21.54
|
Book Value Per Share
2 |
0.0200
|
0.1000
|
0.0900
|
0.0900
|
0.0600
|
0.0400
|
Cash Flow per Share
2 |
0
|
0.0200
|
0.0100
|
0
|
0
|
0
|
Capex
1 |
0.31
|
5.13
|
7.16
|
1.43
|
0.37
|
0.16
|
Capex / Sales
|
521.86%
|
554.57%
|
480.33%
|
34.15%
|
14.05%
|
6.54%
|
Announcement Date
|
28/11/17
|
28/11/18
|
25/11/19
|
12/11/20
|
29/11/21
|
24/11/22
|
|
1st Jan change
|
Capi.
|
---|
| +26.93% | 5.55B | | -33.55% | 3.52B | | -3.74% | 3.03B | | -26.09% | 2.59B | | -10.93% | 2.28B | | +41.50% | 1.88B | | +41.84% | 1.46B | | -12.94% | 1.43B | | +47.62% | 1.42B |
Alternative Medicine
|